Ananda Developments Plc (AQSE:ANA) has published a whitepaper that provides a comprehensive overview of the potential therapeutic benefits and reach of cannabidiol (CBD).
The company says one of the aims of the report is to highlight the "critical gap in robust clinical data to fully understand CBD's efficacy and safety for various medical conditions", with it being intended as a guide for healthcare professionals, researchers, investors and organisations wanting to understand more about the potential of CBD.
Entitled 'An introduction to CBD as a pharmaceutical medicine', the whitepaper looks at the historical uses of cannabis as a medicine and the biological mechanisms underlying CBD's effects, as well as providing a detailed overview of the current state of knowledge regarding CBD's potential benefits in various disease areas, such as chronic pain, autoimmune disorders, and neurodegenerative conditions.
Melissa Sturgess, Ananda's CEO, said: "Ananda Developments is at the forefront of exploring the therapeutic potential of CBD-based medicines.
"This report highlights the vast potential of this fascinating molecule and underscores the need for further clinical research to bring this potential to fruition and offer new treatment options for patients with a variety of conditions."
Ananda said key takeaways from the report include:
- that CBD interacts with a wide range of molecular targets and signalling pathways in the body, potentially impacting numerous conditions
- that CBD exhibits various therapeutic properties, including anti-inflammatory, analgesic, anticonvulsant, and anxiolytic effects
- that existing evidence supports the potential benefits of CBD in treating a wide range of conditions, including chronic pain, various autoimmune diseases, and certain cancers
- and concludes that more clinical trials are needed to prove CBD's efficacy for various conditions and determine optimal formulations, dosages, and administration methods.